As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up awareness of the drug among its expanded patient pool. To that end ...

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and -ultralow metastatic breast cancer. Patients with HR-positive, HER2-low or ...

At the European Society of Medical Oncology (ESMO) Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu (trastuzumab ...

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the medicine’s worth in patients whose cancer has spread to the brain.

Daiichi Sankyo and AstraZeneca’s ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12 Largest prospective ...

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.

Patients with HER2-positive breast cancer benefitted from treatment with Enhertu regardless of brain metastasis. Considerable and durable overall and intracranial activity occurred with Enhertu (T-DXd ...

WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki) has demonstrated a significant progression-free survival (PFS) rate in patients with HER2 ...

Enhertu (fam-trastuzumab deruxtecan-nxki*) is a prescription drug used to treat certain kinds of cancer, including breast cancer. Enhertu is given by intravenous infusion (an injection into a vein ...

WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki) has demonstrated a significant progression-free survival (PFS) rate in patients with ...